Patents Examined by Marcia S. Noble
  • Patent number: 11326148
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: May 10, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Bastian Zimmer, Jason Tchieu
  • Patent number: 11326183
    Abstract: The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 10, 2022
    Assignee: bluebird bio, Inc.
    Inventors: Melissa Bonner, Olivier Negre, Christopher Tipper
  • Patent number: 11274316
    Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 15, 2022
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 11253551
    Abstract: Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: February 22, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Romain Gallet
  • Patent number: 11246896
    Abstract: A conditionally replicating adenovirus were generated that can specifically replicate and express therapeutic genes in neuroendocrine tumors. The promoter-specific expression of the adenoviruses is regulated upstream by an INSM1 (insulinoma-associated-1) promoter that is silent in normal adult tissues but active in developing neuroendocrine cells and neuroendocrine tumors. By placing the I NSM 1-promoter with an insulator and two copies of neuronal restrictive silencer elements in an adenoviral vector, the construct can retain tumor specificity and drive expression of a mutated adenovirus E1A gene (?24E1A) and the herpes simplex virus thymidine kinase gene. The I NSM1-promoter-driven viruses could replicate specifically in the I NSM1-positive cells and I NSM1-specific HSV-tk expression in combination with ganciclovir treatment displayed dose-dependent tumor cell-specific killing in insulinomas.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 15, 2022
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Michael Lan, Mary Breslin
  • Patent number: 11246299
    Abstract: Disease model pigs produced by nuclear transplantation, disease model pigs exhibiting stable phenotypes and production methods thereof are provided. Chimeric pigs for producing disease model pigs exhibiting stable phenotypes, genital glands thereof, and germ cells thereof are also provided. A method for producing a genetically modified disease model pig, includes: (a) transplanting a nucleus of a genetically modified cell into cytoplasm of an egg; (b) developing an obtained clonal embryo in a womb of a female pig to obtain an offspring; and mating the obtained offspring or having the offspring undergo sexual reproduction to further obtain the genetically modified offspring as a disease model pig.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: February 15, 2022
    Assignee: PorMedTec Co., Ltd.
    Inventors: Hiroshi Nagashima, Hitomi Matsunari, Masahito Watanabe
  • Patent number: 11241315
    Abstract: A 3-dimensional block type bone graft includes a plurality of first channels extending horizontally in forward and backward directions and arranged at a predetermined interval in left and right directions and upward and downward directions, a plurality of second channels extending horizontally in the left and right directions and arranged at a predetermined interval in the forward and backward directions and the upward and downward directions, and a plurality of third channels extending vertically in the upward and downward directions and arranged at a predetermined interval in the forward and backward directions and the left and right directions, wherein the first channels, the second channels, and the third channels intersect perpendicularly to each other to communicate with each other so that the first channels, the second channels, and the third channels are configured in a 3-dimensional shape.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: February 8, 2022
    Assignee: EZEKIEL CO., LTD
    Inventor: Jaejoon Lee
  • Patent number: 11240995
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 8, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Jian Ni, Yanan Guo, Rui Huang, Meiling Zhang, Lei Zhao, Yang Bai
  • Patent number: 11236304
    Abstract: Disclosed are a method for preparing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood and a method for differentiating induced pluripotent stem cells into cardiovascular cells. The endocardium-derived adult stem cells are primary culture cells for preparing induced pluripotent stem cells, can be readily isolated and cultured only with a small amount of peripheral blood, have a high proliferation property so as to be storable without generic variation, and can rapidly ensure a cell number so as to be usable in cell therapy. The endocardium-derived adult stem cells have sternness, thereby having high preparation efficiency, and are derived from the endocardium so as to have the epigenetic memory of cardiovascular cells, thereby having an advantage of being able to be differentiated, after preparing induced pluripotent stem cells, into cardiovascular cells such as endothelial cells, smooth muscle cells and cardiomyocytes with a high efficiency.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: February 1, 2022
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Hyo-Soo Kim, Han-Mo Yang, Ju-Young Kim, Joo-Eun Lee
  • Patent number: 11229658
    Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in particular amounts, for use in preventing and/or treating infections and/or inflammations of the lower respiratory tract and/or of the ear in an infant or a young child.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 25, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Norbert Sprenger, Dominique Brassart, Delphine Egli
  • Patent number: 11230719
    Abstract: The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 25, 2022
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Joan M. Robbins, Derek G. Ostertag
  • Patent number: 11226271
    Abstract: Disclosed herein are compositions and methods of fixing and staining rare cells. Further, disclosed herein are methods of identifying circulating tumor cells (CTC). In some embodiments, the method includes: imaging a cell sample to identify a cell of interest; determining a first pixel intensity of a stained nuclear area; determining a second pixel intensity of a background area; calculating a ploidy status of the cell of interest by subtracting the second pixel intensity from the first pixel intensity; and determining whether the cell of interest is a CTC based on the ploidy status. The method may be computer implemented, such that the method uses a machine learning algorithm to identify a feature; process the feature to extract a parameter of interest; analyze the parameter of interest; and when the parameter of interest is greater than or less than a predetermined threshold, classify the cell of interest as a CTC.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: January 18, 2022
    Assignee: X-Zell Biotech Pte Ltd
    Inventor: Sebastian Chakrit Punyaratabandhu Bhakdi
  • Patent number: 11225682
    Abstract: The present invention is concerned with an automated method for obtaining at least one discrete colony from microorganisms or cells comprised in a solution. This method includes a step where acoustic liquid transfer is employed. The present invention further relates to the use of an acoustic liquid transfer device for obtaining at least one discrete colony from micro organisms or cells comprised in a solution. The present invention also relates to an automated method for determining the presence and/or quantity of microorganisms or cells potentially comprised in a solution and to the use of an acoustic liquid transfer device for determining the presence and/or quantity of microorganisms or cells potentially comprised in a solution.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: January 18, 2022
    Assignee: CureVac AG
    Inventors: Isabel Reichert, Fabian Johannes Eber, Christian Mayer, Aniela Wochner
  • Patent number: 11198264
    Abstract: A dried vitrigel membrane is produced by a method including the following steps of (1) a step of keeping a hydrogel in the inside of a wall surface mold with a shape the same as the desired shape disposed on a substrate, and discharging a part of free water within the hydrogel from a gap between the substrate and the wall surface mold; (2) a step of removing the wall surface mold from the top of the substrate; (3) a step of drying the hydrogel to remove the residual free water, thereby fabricating a vitrified dried hydrogel; (4) a step of rehydrating the dried hydrogel to fabricate a vitrigel membrane; and (5) a step of redrying the vitrigel membrane to remove free water, thereby fabricating a vitrified dried vitrigel membrane.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: December 14, 2021
    Assignees: KANTO KAGAKU KABUSHIKI KAISHA
    Inventors: Toshiaki Takezawa, Ayumi Oshikata, Hiroyuki Kuroyama, Tomoya Sawaguchi, Hiroyuki Yamaguchi
  • Patent number: 11193141
    Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: December 7, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
  • Patent number: 11191780
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 7, 2021
    Assignee: Adaptive Biologix, Inc.
    Inventors: Gail K. Naughton, Frank Zeigler, Emmett Pinney
  • Patent number: 11185068
    Abstract: Provided are a diluent and a sperm preservation method using the diluent. The diluent is useful in preservation of sperm with high fertility, and is capable of stably achieving quality control and improving quality of the sperm. Refrigerating or freezing sperm using the diluent for sperm, which includes an aqueous solution containing at least one oligosaccharide selected from the group consisting of a fructo-oligosaccharide, an isomalto-oligosaccharide, a gentio-oligosaccharide, and a galacto-oligosaccharide, can improve the quality of preserved sperm and provide sperm having high fertility, at a reduced cost.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: November 30, 2021
    Assignee: Livestock Improvement Association of Japan, Inc.
    Inventors: Masashi Kinukawa, Katsutoshi Funauchi, Kyoko Uchiyama
  • Patent number: 11185610
    Abstract: Disclosed herein is a method of producing acellular cartilage grafts. The method includes steps of, subjecting a cartilage matrix derived from an animal to alkaline, disinfection and decelluarization treatments. The thus produced cartilage graft is devoid of any cellular matters, while maintaining the porosity and integrity of collagen fibers therein, thus is suitable as a xenograft for host cells to grown thereon. Also disclosed herein is a method for treating osteochondral disease of a subject, in which the present acellular cartilage graft is applied to a lesion site of the subject.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: November 30, 2021
    Assignee: ACRO BIOMEDICAL COMPANY. LTD.
    Inventors: Dar-Jen Hsieh, Ming-Yao Chang
  • Patent number: 11174461
    Abstract: The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 16, 2021
    Assignee: Cynata Therapeutics Limited
    Inventors: Igor Slukvin, Gene Uenishi, Derek Hei, Diana Drier
  • Patent number: 11172657
    Abstract: Provided is a method for developing a secondary organ by using a non-human animal in which organ formation is inhibited, for the purpose of establishing a process for producing a functional cell such as a ? cell within the body of an animal such as a pig, the method including the step of raising a newborn or a fetus of the non-human animal in which organ formation is inhibited by complementing at least a part of the function of the organ whose formation is inhibited.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: November 16, 2021
    Assignee: PORMEDTEC CO., LTD.
    Inventors: Hiroshi Nagashima, Hitomi Matsunari, Kazuaki Nakano, Koki Hasegawa